



Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
www.genzyme.com

For Immediate Release
November 14, 2006

Media Contact:
Erin Emlock
(617) 768-6923

Genzyme Calls for Research Proposals for Renal Innovations Program

CAMBRIDGE, Mass. - Genzyme Corporation is seeking proposals from nephrology researchers for funding under the 2007 Genzyme Renal Innovations Program (GRIP). Over the past five years GRIP has awarded 46 grants, funding more than \$5 million in innovative research projects that advance medical knowledge and practice related to kidney disease.

Genzyme will outline the proposal criteria at the American Society of Nephrology meeting in San Diego this week. An independent medical review board of leaders in nephrology will evaluate the proposals and award grants for a period of one to three years. The board has requested proposals in four key areas: inflammation and vitamin D in renal disease, regenerative pathways (cell and molecular) in renal repair, mechanisms of leukocyte migration/activation in renal injury, and mechanisms of intestinal phosphate absorption.

"The Genzyme Renal Innovations Program has generated some very promising research in many different areas of nephrology, and the number of high quality proposals we receive continues to grow each year," said Robert Guiberteau, M.D., Genzyme's vice president of renal clinical strategy and business development. "This



program is an important component of our commitment to working with the worldwide nephrology community to enhance the care of patients with kidney disease."

This year Genzyme is introducing a new GRIP application process. Applicants must now send Genzyme letters of intent summarizing their research objectives and approach; these are due by January 15, 2007. Applicants will then be notified via email by March 1, 2007 as to whether the review board recommends they submit a full research proposal. Final proposals must reach Genzyme by April 20, 2007.

Grant recipients will be announced at the European Renal Association/European Dialysis and Transplant Association Annual Congress in Barcelona in June 2007. For more information on the 2007 program and application details, please visit www.Renagel.com, www.Hectorol.com or send an email to grip@genzyme.com.

Genzyme awarded 10 GRIP grants in 2006. Recipients of funding were:

- Charles E. Alpers, M.D., University of Washington, Seattle, U.S.A.
- Jeremy Duffield, M.D., Ph.D., Brigham & Women's Hospital, Boston, U.S.A.
- Marie-Luise Gross, M.D. and Anette Melk, M.D., Ph.D., University of Heidelberg, Germany
- Raymond C. Harris, M.D., Vanderbilt University Medical Center, U.S.A.
- Rebecca P. Hughey, Ph.D., University of Pittsburgh, U.S.A.
- Vicki R. Kelley, Ph.D., Brigham & Women's Hospital, Boston, USA
- Jerrold S. Levine, M.D., The University of Illinois at Chicago, USA
- Li-Jun Ma, M.D., Ph.D., Vanderbilt University Medical Center, U.S.A



- Grietje Molema, Ph.D., UMC Groningen, The Netherlands
- Marina Morigi, Ph.D., Mario Negri Institute, Bergamo, Italy

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. This year marks the 25th anniversary of Genzyme's founding. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 8,500 employees in locations spanning the globe and 2005 revenues of \$2.7 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.

This press release contains forward-looking statements including, without limitation, statements about: the effect of GRIP on the treatment of kidney disease and the anticipated timing of the announcement of the GRIP grant recipients. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the actual recipients of future GRIP grants and the results of their research; the ability to evaluate and select the grant recipients in a timely manner; and the risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as



amended, including without limitation the information under the heading "Factors Affecting Future Operating Results" in Genzyme's Quarterly Report on Form 10-Q for the period ended September 30, 2006. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise these statements.

Genzyme[®] is a registered trademark of Genzyme Corporation. All rights reserved.

#

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.